Global Mantle Cell Lymphoma Therapeutics Market 2019-2023

Description Table of
Contents Companies Mentioned

FEATURED COMPANIES

Allergan Plc
AstraZeneca Plc
Celgene Corp.
MORE

Global Mantle Cell Lymphoma Therapeutics Market: About this market

Mantle cell lymphoma therapeutics are available in combination therapy and monotherapy. The mantle cell lymphoma therapeutics market analysis considers sales from the combination therapy and monotherapy segments. Our analysis also considers the sales of mantle cell lymphoma therapeutics in Asia, Europe, North America, and ROW. In 2018, the combination therapy segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as the reduced drug resistance and rising development and commercialization of combination therapies will significantly help the market segment in maintaining its leading position. Also, our global mantle cell lymphoma therapeutics report has observed market growth factors such as recent approvals, introduction of targeted therapies, and growth of geriatric population. However, adverse effects of available therapeutics, limited access to treatment, and presence of stringent regulations may hamper the growth of the mantle cell lymphoma therapeutics industry over the forecast period.

Global Mantle Cell Lymphoma Therapeutics Market: Overview

Recent approvals

The significant unmet need for the treatment of mantle cell lymphoma has given the market vendors scope to develop reliable therapeutics. The rising formulation of therapeutics has prompted many approvals in the last few years, increasing the sales of vendors. As a result, recent approvals will lead to the expansion of the mantle cell lymphoma therapeutics market at a CAGR of over 7% during the forecast period.

Advent of novel therapies

Vendors are formulating advanced therapeutics to cater to the market demand. For instance, kinase inhibitors and gene therapies exhibit high efficacy, increasing their demand. Therefore, this trend will have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global mantle cell lymphoma therapeutics market during the forecast period 2019-2023, contact us.

Competitive Landscape

With the presence of several major players, the global mantle cell lymphoma therapeutics market is concentrated. The robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading mantle cell lymphoma therapeutics manufacturers, which include Allergan Plc, AstraZeneca Plc, Celgene Corp., Johnson & Johnson Services Inc., and Takeda Pharmaceutical Co. Ltd.

Also, the mantle cell lymphoma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

Allergan Plc
AstraZeneca Plc
Celgene Corp.
MORE

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface
2.2 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem
Market characteristics
Market segmentation analysis

PART 04: MARKET SIZING

Market definition
Market sizing 2018
Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product
Comparison by product
Combination therapy - Market size and forecast 2018-2023
Monotherapy - Market size and forecast 2018-2023
Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers
Market challenges

PART 11: MARKET TRENDS

Advent of novel therapies
Research grants and funding
Special drug designations

PART 12: VENDOR LANDSCAPE

Overview
Landscape disruption
Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered
Vendor classification
Market positioning of vendors
Allergan Plc
AstraZeneca Plc
Celgene Corp.
Johnson & Johnson Services Inc.
Takeda Pharmaceutical Co. Ltd.

PART 14: APPENDIX

Research methodology
List of abbreviations
Definition of market positioning of vendors

PART 15: EXPLORE AUTHOR

List of Exhibits

Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Combination therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Combination therapy - Year-over-year growth 2019-2023 (%)
Exhibit 22: Monotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Monotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Proportion of geriatric population in Asia 2007 and 2017
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Pipeline molecules
Exhibit 44: Growth in geriatric population 2013-2017 (%)
Exhibit 45: Side effects of drugs treating mantle cell lymphoma
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Drug designations
Exhibit 48: Recently approved drug designations to drug candidates aimed to treat mantle cell lymphoma
Exhibit 49: Vendor landscape
Exhibit 50: Landscape disruption
Exhibit 51: Vendors covered
Exhibit 52: Vendor classification
Exhibit 53: Market positioning of vendors
Exhibit 54: Allergan Plc - Vendor overview
Exhibit 55: Allergan Plc - Business segments
Exhibit 56: Allergan Plc - Organizational developments
Exhibit 57: Allergan Plc - Geographic focus
Exhibit 58: Allergan Plc - Segment focus
Exhibit 59: Allergan Plc - Key offerings
Exhibit 60: Allergan Plc - Key customers
Exhibit 61: AstraZeneca Plc - Vendor overview
Exhibit 62: AstraZeneca Plc - Product segments
Exhibit 63: AstraZeneca Plc - Organizational developments
Exhibit 64: AstraZeneca Plc - Geographic focus
Exhibit 65: AstraZeneca Plc - Key offerings
Exhibit 66: AstraZeneca Plc - Key customers
Exhibit 67: Celgene Corp. - Vendor overview
Exhibit 68: Celgene Corp. - Business segments
Exhibit 69: Celgene Corp. - Organizational developments
Exhibit 70: Celgene Corp. - Geographic focus
Exhibit 71: Celgene Corp. - Key offerings
Exhibit 72: Celgene Corp. - Key customers
Exhibit 73: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 74: Johnson & Johnson Services, Inc. - Business segments
Exhibit 75: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 76: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 77: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 78: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 79: Johnson & Johnson Services, Inc. - Key customers
Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 81: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 82: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 83: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 84: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 85: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 86: Validation techniques employed for market sizing
Exhibit 87: Definition of market positioning of vendors

Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

Allergan Plc
AstraZeneca Plc
Celgene Corp.
Johnson & Johnson Services Inc.
Takeda Pharmaceutical Co. Ltd.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

FEATURED COMPANIES

RELATED TAGS

RELATED PRODUCTS

Global Non-Hodgkin Lymphoma Therapeutics Market 2021-2025

Global Mantle Cell Lymphoma Market Outlook 2020: Global Opportunity and Demand Analysis, Market Forecast, 2019-2028

Mantle Cell Lymphoma Treatment Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application

Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2022-2026

Mantle Cell Lymphoma - Market Insight, Epidemiology and Market Forecast -2032